Summary
Becton Dickinson and Company (BDX) reported third quarter fiscal year 2023 results with revenues of $4.82 billion, a modest 1.5% increase year-over-year, or 4.1% on a foreign currency-neutral basis. This growth was driven by strong performance in the Medical and Interventional segments, partially offset by a significant decline in COVID-19 related testing revenues within the Life Sciences segment. Net income from continuing operations rose to $460 million ($1.53 per diluted share), up from $390 million ($1.28 per diluted share) in the prior year, indicating improved profitability. The company continues to navigate inflationary pressures and supply chain challenges while focusing on its 'grow, simplify, and empower' strategy, investing in innovation and operational efficiency. Financially, BDX demonstrated solid liquidity with cash and equivalents of $1.98 billion. The company also actively managed its debt, issuing new notes and maintaining compliance with its credit facility covenants. While overall revenue growth was moderate, the underlying segment performance shows resilience, with acquisitions like Parata Systems contributing to growth in the Medication Management Solutions unit. Investors should note the ongoing legal proceedings and regulatory matters, particularly concerning product liability and the Alaris infusion pump, which continue to be areas of focus for management and potential risk.
Financial Highlights
54 data points| Revenue | $4.82B |
| Cost of Revenue | $2.59B |
| Gross Profit | $2.23B |
| R&D Expenses | $337.00M |
| SG&A Expenses | $1.21B |
| Operating Expenses | $4.19B |
| Operating Income | $628.00M |
| Interest Expense | $118.00M |
| Net Income | $460.00M |
| EPS (Basic) | $1.54 |
| EPS (Diluted) | $1.53 |
| Shares Outstanding (Basic) | 284.29M |
| Shares Outstanding (Diluted) | 285.64M |
Key Highlights
- 1Total revenues for the quarter were $4.82 billion, up 1.5% year-over-year (4.1% on a foreign currency-neutral basis).
- 2Net income from continuing operations increased to $460 million ($1.53 per diluted share) from $390 million ($1.28 per diluted share) in the prior year.
- 3The Medical segment showed strong performance with 9.6% reported revenue growth, driven by Medication Management Solutions and Pharmaceutical Systems.
- 4The Interventional segment also grew 6.8% reported, with particular strength in Surgery and Urology & Critical Care products.
- 5Life Sciences segment revenue declined 14.2% due to a significant drop in COVID-19 testing revenues, though the Biosciences unit saw growth.
- 6The company's cash and equivalents and short-term investments stood at $2.07 billion as of March 31, 2023, indicating strong liquidity.
- 7BDX issued new debt, including $800 million in notes and €800 million in Euro-denominated notes, to manage its capital structure.